Shares of Tatva Chintan Pharma Chem zoomed 17 per cent to Rs 2,488.90 on the BSE in Monday’s intraday trade after the company reported a robust set of numbers for the quarter ended September 2021 (Q2FY22), on back of higher revenue. The stock of the specialty chemicals was trading at its highest level since its listing on July 29, 2021.

• Vedanta Outlook for the Week (April 22, 2024 – April 26, 2024)
• Tata Steel Outlook for the Week (April 22, 2024 – April 26, 2024)
• PFC Outlook for the Week (April 22, 2024 – April 26, 2024)
• Piramal Enterprises Outlook for the Week (April 22, 2024 – April 26, 2024)
• MANAPPURAM Outlook for the Week (April 22, 2024 – April 26, 2024)

For Q2FY22, Tatva Chintan’s consolidated net profit jumped over nine-fold to Rs 32.41 crore as against Rs 3.56 crore in Q2FY21. Revenue from operations during the quarter more than doubled to Rs 123.62 crore from Rs 60.04 crore in the corresponding quarter of previous fiscal. The company’s, earnings before interest, tax, depreciation and amortization (ebitda) margin improved to 31.3 per cent from 13.85 per cent.